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Abstract
Background: Long-acting somatostatin analogues delivered parenterally are the most widely used medical treatment in
acromegaly. This patient-reported outcomes survey was designed to assess the impact of chronic injections on subjects with
acromegaly.
Methods: The survey was conducted in nine pituitary centres in Germany, UK and The Netherlands. The questionnaire was
developed by endocrinologists and covered aspects of acromegaly symptoms, injection-related manifestations, emotional
and daily life impact, treatment satisfaction and unmet medical needs.
Results: In total, 195 patients participated, of which 112 (57%) were on octreotide (Sandostatin LAR) and 83 (43%) on
lanreotide (Somatuline Depot). The majority (O70%) of patients reported acromegaly symptoms despite treatment. A total
of 52% of patients reported that their symptoms worsen towards the end of the dosing interval. Administration site pain
lasting up to a week following injection was the most frequently reported injection-related symptom (70% of patients).
Other injection site reactions included nodules (38%), swelling (28%), bruising (16%), scar tissue (8%) and inflammation (7%).
Injection burden was similar between octreotide and lanreotide. Only a minority of patients received injections at home (17%)
and 5% were self-injecting. Over a third of patients indicated a feeling of loss of independence due to the injections, and 16%
reported repeated work loss days. Despite the physical, emotional and daily life impact of injections, patients were satisfied
with their treatment, yet reported that modifications that would offer major improvement over current care would be
‘avoiding injections’ and ‘better symptom control’.
Conclusion: Lifelong injections of long-acting somatostatin analogues have significant burden on the functioning,
well-being and daily lives of patients with acromegaly.
European Journal of
Endocrinology
(2016) 174, 355–362
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Introduction
Acromegaly is a rare debilitating endocrine disease
characterised by hypersecretion of growth hormone
(GH), occurring almost exclusively as a result of a benign
pituitary adenoma (1).
The disease is associated with significantly increased
morbidity, mortality, mainly due to cardiovascular,
cerebrovascular and respiratory diseases and decreased
quality of life (1, 2, 3).
Somatostatin receptor ligands ((SRLs): octreotide and
lanreotide) are used as first-line medical treatment for
patients with inadequate response to surgery and/or
radiotherapy, or for those in whom surgery and/or radio-
therapy are not indicated (4, 5, 6, 7, 8, 9, 10). These are
long-acting depot formulations administered as monthly
intramuscular or deep subcutaneous injection (7, 10).
Published literature on patient-reported outcomes
(PROs) in acromegaly is scarce. Quality of life and illness
perception studies have been mainly performed in cross-
sectional settings, in which small group sizes and
heterogeneity of the population studied precluded strong
conclusions on outcome of a specific treatment (11, 12).
Next, studies have focused on acromegaly symptoms or
disease-specific quality of life without specifically addres-
sing the impact of chronic parenteral injections (13).
To date, no qualified questionnaire is available addressing
these issues. This PRO survey was designed to compre-
hensively assess for the first time the impact of chronic
administration of long-acting SRL injections on the
physical and psychological well-being and the everyday
lives of patients with acromegaly (11, 12, 13).
Patients and methods
Survey design
This was a multi-centre, observational survey, in 195
patients with acromegaly managed routinely with parent-
eral SRLs (14). The survey protocol was developed with
internationally recognised experts in endocrinology, experi-
enced in the care of patients with acromegaly with medical
treatment, and received approval by local Ethics Commit-
tees in eight endocrinology centres and one neurosurgical
centre (Erlangen), specialised in acromegaly in three
European countries, Germany, UK and The Netherlands.
Participation was suggested to all acromegaly patients
treated by the participating sites. Patients were eligible
for participation if they were above 18, diagnosed with
acromegaly, treated with regular parenteral SRL injections
for a minimum of 6 months and able to successfully
complete an interview and independently respond to the
questions. The survey questionnaire was administered
after a written informed consent was obtained, and data
collected were pseudonymised for confidentiality.
Retrospective clinical information including acrome-
galy disease history, IGF1 assays, serum IGF1 levels and
SRL treatment history were collected from the patients’
medical files. The treating physician was asked to evaluate
the patients’ response to treatment. The patient ques-
tionnaire was developed to capture the impact and burden
of chronic parenteral injections as well as the patient’s
satisfaction with treatment.
This questionnaire is composed of five major sections:
i) acromegaly signs and symptoms since the last injection
(13 items), graded by severity from none (0) to severe (3)
and their impact on patients (four statements);
ii) injection-related physical burden, based on patients’
overall historical experience with SRLs treatment (19 items
plus two statements) (graded by burden from 0Znone/not
troublesome to 3Zvery troublesome); iii) injection-related
emotional burden (seven statements) (graded by frequency
from 0Znot at all to 3Z often); iv) injection-related
everyday life burden throughout the entire treatment
experience (12 items); and v) overall treatment satisfaction
(two items) and unmet medical needs (15 yes/no
statements).
The questionnaire was interviewer administered by
specifically trained research nurses at the sites either by
telephone or in person and took w30 min to complete.
Patients’ responses were captured ‘as is’ with no amend-
ments or interpretations by the interviewer.
Statistical considerations and data analysis
This observational survey is descriptive in nature (14).
No formal hypothesis testing was used (15, 16). In total,
195 participants provided a sample size clinically sufficient
to represent real-life population of acromegaly patients in
the selected sites and to show trends for the burden and/or
satisfaction with chronic injections in this rare disease.
This sample size is alignedwith other observational studies
in acromegaly (17, 18). A formal analysis plan predefined
the analyses populations and the descriptive variables to
be assessed (15).
Post hoc exploratory analysis (19) was employed
to analyse differences between the two SRLs octreotide
and lanreotide, between biochemically controlled and
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non-controlled patients (age-normalised IGF1 SDS %2.0;
O2.0) as well as patients with partially controlled and
non-controlled disease (SDS%2.6; O2.6).
Statistical analysis was conducted between groups with
the unequal variance (uv) t test (20). Missing data were not
imputed, hence not included in the analysis (16, 20).
To allow comparison across different laboratories, all
IGF1 values were translated into SDS using assay-specific
reference intervals stratified by age and sex, as recently
published and recommended in the international con-
sensus criteria (21). To that purpose, recently published
reference intervals and the formula zZ(((IGF1/M)L)-
1)/(L!S)) were used for IGF1 values generated on the
IDS-iSYS assay (22). For the two laboratories using
the Immulite platform, SDS was calculated based on the
respective reference intervals and the formula zZ(log
IGF1-log mean)/logSD (23).
Patient population
A total of 301 acromegaly patients were invited to
participate between November 2012 and June 2013. In
total, 201 patients signed an informed consent, five
patients were lost to follow-up and one patient was
excluded from the analysis due to incomplete SRL
treatment data. The 195 eligible patients were distributed
between Germany (five sites), 102 patients; UK (three
sites), 70 patients; and The Netherlands (one site), 23
participants. Table 1 summarises the baseline charac-
teristics of the enrolled population.
In total, 112 patients (57.4%) were receiving octreo-
tide while 83 patients (42.6%) were receiving lanreotide.
The most commonly prescribed administration frequency
was every 28 days in 138 patients (69.7%), while in 28
patients (13.8%), this was shorter (21 days), and in 11.3%
of patients, this was longer (14 patients – 42 days and eight
patients – 56 days). The mean treatment duration with
SRLs in the enrolled population was 6.6 years (range 0.5–
18.2 years). In total, 42 patients (21.1%) received
dopamine agonists and 33 patients (16.6%) pegvisomant,
in combination with SRLs. A total of 70 patients (36%) had
been switched to their current treatment from a different
medical treatment for acromegaly: from dopamine ago-
nists to SRLs (20 of 70) and between SRLs (octreotide to
lanreotide (19 out of 70), lanreotide to octreotide (three
out of 70), daily s.c. octreotide to long-acting SRLs (three
out of 70) and data not provided (25 patients)). The most
common reason for a switch was a lack of disease control
(49%). Other reasons to switch were newly available
treatments (16%), adverse reactions (11%) and injection-
related symptoms/signs (7%).
Results
Acromegaly signs and symptoms
The majority of patients (O70%) reported acromegaly
symptoms, with fatigue, joint pains, snoring, excessive
sweating and headaches being the most frequently
described. In total, 52% of all patients reported that their
symptoms worsened towards the end of the dosing
interval and 62% that symptoms interfered with their
daily life (Fig. 1).
Table 1 Baseline characteristics.
Patients’ characteristics n %
Gender
Male (n/%) 103 52.8
Female (n/%) 92 47.2
Age (based on year of birth)
Mean (years) 59
Minimum (years) 24
Maximum (years) 89
Median (years) 61
S.D. 14.0
Duration of disease
!10 years (n/%) 99 50.8
Between 10 and 20 years (n/%) 61 31.3
O20 years (n/%) 35 17.9
Unknown (n/%) 0 0.0
Physician assessment of response to SSA treatment
Responder (n/%) 104 53.3
Partial responder (n/%) 71 36.4
Non-responder (n/%) 12 6.2
Missing information 8 4.1
IGF1 (n) 187
Mean (ng/ml) 244
Minimum (ng/ml) 45
Maximum (ng/ml) 1224
Median (ng/ml) 202
S.D. 150
Missing information (n) 8
Biochemical control (n) (SDS refers to IGF1)
Controlled (SDS %2.0) 71 36.4
Not controlled (SDS O2.0) 109 55.9
Controlled plus ‘partially’ controlled (SDS%2.6) 101 51.8
Missing information 15 7.7
Drug and dosage
Octreotide (n/%) 112 57.4
10 mg (n/%) 16 8.2
20 mg (n/%) 28 14.4
30 mg (n/%) 68 34.9
Lanreotide (n/%) 83 42.6
60 mg (n/%) 9 4.6
90 mg (n/%) 22 11.3
120 mg (n/%) 52 26.7
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There was no statistically significant difference in the
mean acromegaly symptom scores between biochemically
controlled or partially controlled and uncontrolled
patients (Supplementary Tables 4 and 5, see section on
supplementary data given at the end of this article).
Injection-related signs and symptoms
The major injection-related signs and symptoms reported
by the patients are summarised in Fig. 2 and provided in
detail in Supplementary Tables 1, 2, and 3, see section on
supplementary data given at the end of this article.
Injection-related pain was the item scored highest by
patients, with a mean severity burden of 0.97 (S.D.Z0.80),
followed by bowel problems (meanZ0.90; S.D.Z0.99).
Hardness at the injection site was the highest scored skin
pathology (meanZ0.64; S.D.Z0.78), followed by nodules
(meanZ0.54; S.D.Z0.79). More than a third (36%) of
patients reported pain for days after their injection and
15% for a week after their injection.
Overall, the treatment burden for octreotide and
lanreotide patients was similar. However, patients on
octreotide reported pain for a longer duration after
injections. On the other hand, patients treated with
lanreotide tended to develop more skin nodules, swelling,
bruising and dermatitis compared with those treated with
octreotide, as well as more bowel problems (Fig. 3).
Emotional impact
Figure 4 shows that one-third of patients in the survey
group felt emotionally burdened by the injections, with
36% of them reporting a ‘loss of independence’ as a
consequence of their treatment.
Everyday life impact
The majority of patients received their SRL injections at
their general practitioner’s (GP’s) office or hospital out-
patient clinic (68%), and in most cases, these were
administered by the nurse or the physician (39 and 33%
respectively). This was remarkably similar between the
treatments, and only 17% of patients (16% of octreotide
and 18% of lanreotide-receiving patients) reported that
they received the injections at home. Only eight patients
(10%) treated with lanreotide reported they were self-
injecting their medication (2% on octreotide). Germany,
UK and The Netherlands showed notable similarity
regarding the above treatment patterns.
Transportation to and from the GP’s office or clinic to
receive injections was considered convenient or very
convenient by 62% of the survey population, while 22%
of patients considered the travel as somewhat or very
Symptoms become worse
towards the end of injection cycle
Joint pains
Fatigue
Snoring
Excessive sweating
Headache
100 20 30 40
Percentage of respondents (total population n=195)
50 60 70 80 90 100%
%
Mild (1)
Most frequently patient reported acromegaly symptoms
Moderate (2) Severe (3)None (0)
10
Often (3)
0 20 30 40
Percentage of respondents (total population n=195)
Patient reported impact of acromegaly symptoms
50 60 70 80 90 100
Sometimes (2)Rarely (1) Very often (4) Always (5)Never (0)
Acromegaly symptoms are
different between injections
Acromegaly symptoms interfere
with my daily life and work
Acromegaly symptoms make
me feel fed up and frustrated
Figure 1
Acromegaly symptoms and their impact on patients.
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Little troublesome (1)
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Percentage of respondents (total population n=195)
Injection-related symptoms (total population n=195)
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Somewhat troublesome (2)
Very troublesome (3)
Not troublesome/none (0)
Pain at injection site
(highest per patient)
Pain at injection
site during injection
Pain at injection
site days after injection
Pain at injection
site week after injection
Nodules
Swelling
Bruising
Inflammation of skin
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Figure 2
Injection-related symptoms (total population; nZ195).
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inconvenient. In total, 7% of participants were routinely
accompanied by an additional person. The total time
required for the injections, including travel; waiting;
preparation; and administration of the injection, consul-
tation and arranging the next appointment, was reported
as 67 min (range 0 (for self-injection) – 300 min; S.D.
48 min) per injection on average.
Work loss due to the injections was reported by 16.6%
of the population, with mean of 11 times/year.
In total, 44% of the patients had encountered
problems with the preparation and administration of the
injections at any time during their SRL treatment history,
with an average of 7.6 (range 1–50; S.D.Z9.3) problems per
patient (during a mean of 6.6 years of treatment). The
majority of these cases (42%) were clogged or broken
needles, often necessitating a second injection (27% of all
consequences).
Patients’ satisfaction and unmet medical needs
Patients’ satisfaction with their SRL treatment is sum-
marised in Fig. 5. Patients were generally satisfied with
their treatment, yet reported that an ‘oral therapy’ (48%),
‘a treatment to avoid injections’ (44%) and a ‘treatment
with better symptom control’ (41%) would be potential
major improvements over their current treatment. Self-
injection or at-home injection was not considered as a
major improvement by many patients (12 and 10%
respectively). There was no statistically significant
difference between biochemically controlled or partially
controlled and uncontrolled patients (Supplementary
Tables 4 and 5).
Discussion
The high participation rate in this survey (201 enrolled out
of a 301 eligible patients) suggests that this survey
represents a real-world population of patients with
acromegaly treated with SRLs at the respective participat-
ing endocrinology centres in Europe. Treatment and
disease characteristics are similar to clinical trials and
registries data in the literature, except for a higher age
and a lower biochemical control rate (SDS %2.0; 36.4%)
(2, 4, 7, 8, 10, 13, 17). This may reflect differences between
real-world practices and randomised controlled trials and
is also consistent with recently published data (13, 18).
The majority of patients (O70%) reported symptoms
consistent with acromegaly despite treatment. The preva-
lence of reported acromegaly symptoms was higher in this
cohort as compared with clinical trial literature (4, 7, 8,
10), yet is comparable to that reported in the observational
SODA registry (17).
While the physical burden of chronic injections
as reported in this survey is consistent with the literature
(4, 5, 6, 7, 8, 9, 10), the incidence of injection site reactions
is distinctly higher, specifically for injection site pain,
nodules, swelling or bruising. The longer duration of pain
following octreotide injections and higher incidence
of skin pathologies, particularly nodule formation, on
lanreotide, is interesting, reported here for the first time,
and reflects clinical practice experience. Injection patterns
were similar between octreotide and lanreotide (including
the incidence of home injections), which suggest that
10
Little troublesome (1)
0 20 30 40
Percentage of respondents
Injection-related symptoms (octreotide n=112 vs. lanreotide n=83)
50 60 70 80 90 100
Somewhat troublesome (2)
Very troublesome (3)
Not troublesome/none (0)
P=0.0458
Pain at injection site hours
after injection–lanreotide
Pain at injection site hours
after injection–octreotide
P=0.0007
Pain at injection site days
after injection–lanreotide
Pain at injection site days
after injection–octreotide
P=0.0008
Nodules–lanreotide
Nodules–octreotide
P=0.0076
Bowel problems–lanreotide
Bowel problems–octreotide
%
Figure 3
Injection-related symptoms (octreotide and lanreotide
populations).
I am frustrated and fed up
with these injections
These injections frustrate and
bother me more and more
I get emotional, anxious or upset
I try to avoid thinking
and talking of them
I am emotionally numb–
I don’t care
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Rarely (1)
0 20 30 40
Percentage of respondents (total population n=195)
Stressful event statement
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These injections make me
feel a loss of independence
Figure 4
Emotional impact of the injections.
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home or self-injection rates are generally low in the
participating European countries and are considerably
lower than reported for the USA (SODA) (17, 24).
The similarities in the reported issues encountered
during injections (e.g. high frequency of clogged needles),
in different countries imply that these problems are
inherent to the medications themselves and their mode
of administration and less so affected by the standard of
care in a given country. Time loss due to injections (on
average over 0100 h/injection) is corroborated with the
literature (10, 17).
The majority of patients (O70%) reported acromegaly
symptoms, with fatigue, joint pains, snoring, excessive
sweating and headaches being the most frequently
described. An unexpected finding was that half (52%) of
the participants reported that their symptoms became
worse towards the end of the dosing interval (‘break-
through symptoms’). Based on these results, it may be
speculated that the shortened injection interval reported
by some patients could have been due to breakthrough
symptoms rather than to inadequate control of IGF1
levels. Our data show for the very first time that break-
through symptoms reported by patients are a considerable
treatment burden in general practice and deserve the
attention of the treating physician.
Post hoc exploratory analyses detected no significant
differences between biochemically controlled and non-
controlled patients (SDS %2.0; O2.0) as well as patients
partially controlled and non-controlled (SDS%2.6;O2.6),
with regards to patient-reported symptoms burden,
physical and emotional burden or overall treatment
satisfaction. No correlation was noted between the
objective biochemical parameter IGF1, the main treat-
ment focus and the subjective sense of well-being reported
by patients enrolled in this survey, which are regularly
managed with SRLs. This is in keeping with previous
published data (11, 12, 13, 18).
Despite the considerable treatment burden noted with
chronic injections, patients were both satisfied with their
treatment and confident that it provided benefit to them.
This is not surprising, as SRL injections provide an effective
treatment (4, 7, 8, 10, 24). Patients still reported that
potential major improvements over their current treat-
ment would be one that would avoid injections and
a treatment with better symptom control.
This PRO survey has some limitations. It is an
uncontrolled, observational survey that provides a snap-
shot in time on PROs related to treatment with SRLs (14).
As such, causative effects on outcomes cannot be
determined (14, 19). Assessing PROs in acromegaly
patients treated with other medical treatments may shed
more light on the etiology of symptoms and their possible
mediation by IGF1 effects vs GH effects. Assessing PROs in
patients with no functioning adenoma may discriminate
between non-specific symptoms related to the tumour
location/burden and symptoms related to excess GH. The
survey questionnaire used in our present study was
specifically designed to investigate the burden of monthly
SRL injections (injection site reactions, breakthrough
symptoms, day-to-day burden of chronic injections
provided by health care providers in the clinic and
other). New survey questionnaires could be developed
for use in future studies that are specific to other
treatments and/or indications and may help to better
understand the etiology of symptoms experienced by
acromegaly patients.
Despite the broad inclusion criteria and a high
participation rate, an enrolment bias towards more
burdened acromegaly patients cannot be excluded, given
the relatively low rate of biochemical control and the
frequency of symptoms reported, although, as suggested
previously, this may reflect the real-world population in
contrast to clinical trials. In addition, patients were
recruited and interviewed by the research nurses at
specialised endocrinology centres, with whom patients
had established good and long-standing relationships.
This may have led to an underreporting bias.
These novel patient-reported data, which were eval-
uated for the first time in such comprehensive fashion,
reflect the way that chronic injections of long-acting SRLs
impact the functioning, well-being and daily lives of
patients with acromegaly. These effects are substantial and
Extremely confident (+2)
Very confident (+1)
Somewhat confident (0)
Little confident (–1)
Not at all confident (–2)
50 10 15 20
Percentage of respondents (total population n=195)
25 30 35 40 45 50%
Extremely satisfied (+3)
Very satisfied (+2)
Satisfied (+1)
Somewhat satisfied (0)
Dissatisfied (–1)
Very dissatisfied (–2)
Extremely dissatisfied (–3)
22
15
26
36
14
4
4
1
27
4
2
Mean confidence score 0.40, S.D. 0.92
Mean satisfaction score 1.21, S.D. 1.24
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Figure 5
Patient overall satisfaction and confidence.
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remarkably consistent across both octreotide and lanreo-
tide patients and in the three European countries studied.
It appears that variation of symptom control throughout
the treatment interval is not a negligible issue that has
not yet been addressed in studies primarily focusing on
efficacy. Future studies should further explore the clinical
significance of breakthrough symptoms and potential
strategies to improve stability of control.
In parallel to biochemical disease control, treating
physicians and future clinical studies should consider
assessment of PRO measures, as clinical symptoms and
patients’ well-being. PRO studies such as the current
survey highlight the need for better therapeutic alterna-
tives for optimal control of acromegaly.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EJE-15-1042.
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